Skip to main content
Jianmin Pharmaceutical Group Co., Ltd. logo

Jianmin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 600976 ISIN · CNE000001HB7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2023-03-14 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600976

About Jianmin Pharmaceutical Group Co., Ltd.

https://www.whjm.com/

Jianmin Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical enterprise with a heritage dating back to 1637. The company focuses on the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern healthcare products. Its core portfolio emphasizes pediatric health, gynecological treatments, and chronic disease management. Key products include Longmu Zhuanggu Granules, recognized for supporting bone development and overall health in children. The group integrates traditional pharmacological wisdom with contemporary biotechnology and standardized production processes. Jianmin Group operates through a comprehensive value chain encompassing raw material sourcing, advanced manufacturing, and a distribution network. By leveraging its status as a time-honored brand, the company maintains a strong market position in the pediatric TCM segment while expanding its presence in general wellness and prescription drug markets.

Recent filings

Filing Released Lang Actions
健民集团关于运用自有闲置资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about its plan to use idle funds for cash management by investing in low-risk financial products. It details the investment amount, risk considerations, approval procedures, and impact on the company. There are no financial statements or detailed financial performance data presented, nor is it a transcript, report, or presentation. The document is a formal announcement regarding capital management activities, specifically about financing and investment of idle funds. This fits best under the category of Capital/Financing Update (CAP). The document length is 3439 characters, which is consistent with an announcement rather than a full report.
2023-03-14 Chinese
健民集团2022年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2022 年度内部控制评价报告' which translates to '2022 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2022. The content includes detailed descriptions of internal control scope, standards, defect classifications, and audit opinions. It is a comprehensive report on internal control evaluation rather than a brief announcement or certification. The document length is 4418 characters, which is relatively short but contains substantive content and detailed evaluation results, not just a notice of report publication. The document is not an annual report (10-K), earnings release, or other financial statement but specifically an internal control evaluation report, which aligns with the category of Audit Report / Information (AR). Therefore, the most appropriate classification is AR with high confidence. FY 2022
2023-03-14 Chinese
健民集团第十届董事会第七次会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 7th meeting of the 10th Board of Directors of 健民药业集团股份有限公司. It includes voting results on various reports and proposals such as the 2022 President's work report, 2022 Board work report, 2022 independent directors' report, 2022 audit committee report, 2022 financial statements, profit distribution plan, and other operational and governance matters. The document also references that many of these reports will be submitted to the shareholders' meeting for approval and provides links to where the full reports can be found. The document is not the full annual report or financial statements itself but rather a board meeting resolution announcement with voting results and summaries. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters, and it primarily reports voting outcomes and resolutions rather than containing full financial data or detailed reports themselves, so it is not an Annual Report (10-K) or Interim Report (IR). Therefore, the best classification is DVA with high confidence.
2023-03-14 Chinese
关于健民药业集团股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告(众环专字(2023)0100112号)
Audit Report / Information Classification · 95% confidence The document is a specialized audit report issued by Zhongshenzhonghuan Certified Public Accountants LLP regarding the non-operating fund occupation and other related party fund transactions of Jianmin Pharmaceutical Group Co., Ltd. for the year ended December 31, 2022. It references the audit of the 2022 consolidated financial statements and provides an opinion on a specific summary table related to non-operating fund occupation and related party transactions. The document includes detailed financial data and audit procedures, indicating it is a standalone audit report rather than a full annual report or a simple announcement. It is not a certification letter or a brief announcement but a detailed audit opinion on a specific financial matter. Therefore, the appropriate classification is Audit Report / Information (AR).
2023-03-14 Chinese
健民集团2022年年度报告
Annual Report Classification · 100% confidence The document is titled '健民药业集团股份有限公司 2022 年年度报告' which translates to 'Jianmin Pharmaceutical Group Co., Ltd. 2022 Annual Report'. It contains detailed financial data for the year 2022, including revenue, net profit, quarterly financial data, non-recurring gains and losses, management discussion and analysis, company overview, governance, and social responsibility sections. The document is lengthy (15,000 characters) and includes comprehensive financial statements and analysis, not just an announcement or summary. It also includes auditor's report references and signatures, confirming it is the full annual report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-03-14 Chinese
健民集团关于向中国人口福利基金会捐赠的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding a charitable donation to a foundation. It details the donation amount, recipient, purpose, and terms of the donation. There is no financial data, no mention of financial results, no regulatory filings, no management changes, no voting results, no capital changes, or other typical financial report content. The document is a formal announcement of a corporate social responsibility action, specifically a donation. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-03-14 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.